spot_img
Sunday, August 14, 2022
More
    HomeHealthBristol Myers Squibb to buy Turning Point Therapeutics for $4.1 billion

    Bristol Myers Squibb to buy Turning Point Therapeutics for $4.1 billion

    -



    Bristol Myers Squibb mentioned Friday that it’s buying Turning Level Therapeutics, a biotech that’s creating medicines that combat most cancers by concentrating on particular mutations, for $4.1 billion, or $76 per share.

    Turning Level’s lead drug, repotrectinib, is being examined to deal with non-small cell lung most cancers tumors that comprise a genetic alteration often called Ros1. Different remedies, resembling Pfizer’s Xalkori and Roche’s Rozlytrek, are authorised to deal with these cancers, however Bristol mentioned that information appear to point that repotrectinib will work longer and doubtlessly produce other benefits.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,435FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts